DOCSLIB.ORG

Fate Mapping Analysis of Lymphoid Cells Expressing the Nkp46 Cell Surface Receptor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fate Mapping Analysis of Lymphoid Cells Expressing the Nkp46 Cell Surface Receptor Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor Emilie Narni-Mancinellia,b,c,1, Julie Chaixa,b,c,1,2, Aurore Fenisa,b,c, Yann M. Kerdilesa,b,c, Nadia Yessaada,b,c, Ana Reyndersa,b,c, Claude Gregoirea,b,c, Herve Luchea,b,c, Sophie Ugolinia,b,c, Elena Tomaselloa,b,c, Thierry Walzera,b,c,3, and Eric Viviera,b,c,d,4 aCentre d’Immunologie de Marseille-Luminy, Université de la Méditerranée UM 631, Campus de Luminy Case 906, 13288 Marseille, France; bInstitut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S 631, 13009 Marseille, France; cCentre National de la Recherche Scientifique, Unité Mixte de Recherche 6102, 13288 Marseille, France; and dAssistance Publique, Hôpitaux de Marseille, Hôpital de la Conception, 13385 Marseille, France Edited* by Christophe Benoist, Harvard Medical School, Boston, MA, and approved September 19, 2011 (received for review July 26, 2011) NKp46 is a cell surface receptor expressed on natural killer (NK) the selectivity of expression of eGFP in NDE mice mirrored that of cells, on a minute subset of T cells, and on a population of innate endogenous NKp46 in a fraction of transgenic mice, variegation at lymphoid cells that produce IL-22 and express the transcription the transgenic locus led to unpredictable variation in the pene- factor retinoid-related orphan receptor (ROR)-γt, referred to as NK trance of the transgene expression in mouse littermates. Another cell receptor (NKR)+ROR-γt+ cells. Here we describe Nkp46iCre knock- transgenic mouse expressing the improved Cre (iCre) recombinase in mice in which the gene encoding the improved Cre (iCre) recom- under the control of the Nkp46 promoter was recently reported binase was inserted into the Nkp46 locus. This mouse was used to and crossed to eGFP reporter mice (29). However, on average noninvasively trace cells expressing NKp46 in vivo. Fate mapping only 80% of NKp46+ NK cells expressed eGFP, and no eGFP experiments demonstrated the stable expression of NKp46 on expression was detected in T cells, suggesting that the regulation NK cells and allowed a reappraisal of the sequential steps of NK of the iCre transgene expression in this model did not match with cell maturation. NKp46 genetic tracing also showed that gut the endogenous expression of NKp46, hence hampering the use NKR+ROR-γt+ and NK cells represent two distinct lineages. In addi- of these mice for selective gene targeting in NKp46+ cells. To tion, the genetic heterogeneity of liver NK cells was evidenced. circumvent these caveats of expression pattern that are classically Finally, Nkp46iCre mice also represent a unique mouse model of observed in transgenic mice (30), we generated a knock-in mouse conditional mutagenesis specifically in NKp46+ cells, paving the line in which the gene encoded the improved recombinase (icre) way for further developments in the biology of NKp46+ NK, T, and was inserted by homologous recombination at the 3′ end of Nkp46, NKR+ROR-γt+ cells. in an attempt to drive its expression by all endogenous Nkp46 regulatory elements. Here we report that iCre expression faithfully natural killer cell differentiation | NKp46 knock-in corresponds to the endogenous expression of NKp46, on bona fide NK cells, on a subset of gut ILCs, as well as on very discrete sub- atural killer (NK) cells are effector and regulatory lym- populations of T cells, allowing us to trace the fate of the het- Nphocytes of the innate immune system that contribute to erogeneous NKp46+ populations of cells. tumor surveillance, hematopoietic allograft rejection, control of microbial infections, and pregnancy (1). NK cells can be cyto- Results toxic and secrete an array of cytokines and chemokines, such as Characterization of Nkp46iCre Knock-in Mice. We generated a knock- IFN-γ and β-chemokines. in mouse line in which icre was inserted by homologous re- NKp46 (NCR1, CD335) is a marker of NK cells in all mam- combination at the 3′ end of the Nkp46 gene (Fig. 1A and Fig. S1). iCre/wt malian species tested so far, including human, nonhuman pri- Nkp46 mice were obtained at Mendelian frequencies, de- mates, mouse, rat, and cow (2–8). NKp46 is an Ig-like superfamily veloped normally, were fertile, and showed no significant varia- cell surface receptor, which is a member of a group of natural tions in the numbers of lymphoid and myeloid subsets compared cytotoxicity receptors (NCRs) with NKp44 (NCR2, CD336) and with wild-type (wt) littermates. NK cell counts, phenotype, and iCre/wt NKp30 (NCR3, CD337) (9). NKp46 is associated with immunor- in vitro effector function were not affected in Nkp46 mice, eceptor tyrosine-based activation motif-bearing polypeptides, such despite a down-regulation in the density of cell surface NKp46 that + as CD3-ζ and FcR-γ, which transduce potent activating signals did not alter the percentage of NKp46 NK cells (Fig. S2). eYFP/wt upon triggering (4, 10). NKp46 is involved in tumor cell recogni- Rosa26eYFP reporter mice (R26R ) carry under the fl tion via still-unidentified ligands (11, 12) and has also been de- Rosa26 promoter a loxP- anked STOP sequence that prevents the scribed as binding viral hemagglutinins (13, 14). Finally, it has been expression of the downstream eYFP gene. The STOP sequence is reported that NK cells contribute via NKp46 to type I diabetes removed and eYFP is expressed in cells where iCre is expressed through the destruction of pancreatic β-islets (15). NKp46 is found on all mature NK cells regardless of their anatomic localization in both human and mouse. The selective expression of NKp46 on Author contributions: E.N.-M., T.W., and E.V. designed research; E.N.-M., J.C., A.F., Y.M.K., N.Y., A.R., E.T., and T.W. performed research; J.C., A.F., C.G., H.L., and T.W. contributed NK cells has two reported exceptions: rare T-cell subsets (6, 16, new reagents/analytic tools; E.N.-M., S.U., and E.V. analyzed data; and E.N.-M. and + 17) and a mucosal population of NKp46 innate lymphoid cells E.V. wrote the paper. (ILCs) that express the transcription factor retinoid-related or- Conflict of interest statement: E.V. is a co-founder and shareholder of Innate-Pharma. γ phan receptor (ROR)- t and produce IL-22, a key cytokine for the *This Direct Submission article had a prearranged editor. – activation and defense of epithelial cells (18 28). 1E.N.-M. and J.C. contributed equally to this work. The NKp46 amino acid sequence is highly conserved in all 2Present address: Abramson Family Cancer Research Institute, Department of Medicine, mammals. The striking homologies in the regulatory regions of the University of Pennsylvania, Philadelphia, PA 19104. NKP46 gene from opossum to human prompted us to generate 3Present address: Université de Lyon, Institut National de la Santé et de la Recherche a transgenic mouse line, called NDE, in which the diphtheria toxin Médicale U851, F-69007 Lyon, France. receptor (DTR) and the enhanced green fluorescent protein 4To whom correspondence should be addressed. E-mail: [email protected]. (eGFP) expression were driven by a 450-bp conserved promoter This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. region (P1) upstream of Nkp46 (Ncr1) start codon (6). Although 1073/pnas.1112064108/-/DCSupplemental. 18324–18329 | PNAS | November 8, 2011 | vol. 108 | no. 45 www.pnas.org/cgi/doi/10.1073/pnas.1112064108 Downloaded by guest on September 25, 2021 STOP Spleen Liver A A 4 3 — ) NKp46/Ncr1 IRES Cre ) 6 5 DT 3 2 Gated on splenic lymphocytes 2 B 1 1 NK cells (x10 NK cells (x10 *** *** 0 0 BM LN 2 6 ) ) 5 4 0 eYFP NK1.1 CD3 NKp46 4 1 2 Gated on NK1.1+/NKp46+/CD3- NK cells C BM BLOOD SPLEEN LNs NK cells (x10 *** NK cells (x1 *** 0 0 B Spleen Liver BM LN B LUNG THYMUS MLNs NKp46iCre T R26ReYFP NKp46iCre NKT NK 0 50 100 150 eYFP % of non-treated D B cells CD4+ αβT cells CD8+ αβT cells NKT Fig. 2. Specific depletion of NK cells in DT-treated NKp46iCreR26RDTR mice. Groups of mice were treated i.v. with DT, and cell recovery was analyzed 2 d later. (A) NK cell proportions among live leukocytes of nontreated (−)or DT-treated mice. (B) Lymphoid cell populations recovery expressed as per- cent of cell numbers in nontreated mice (mean ± SEM). n ≥ 12 per group and DCs neutrophils monocytes macrophages per organ. ***P < 0.001. induced a depletion of NK cells in blood, spleen, BM, and LN (Fig. 2A and Fig. S4). The depletion induced by DT treatment in eYFP NKp46iCreR26RDTR mice was restricted to NK cells (Fig. 2B), Fig. 1. Faithful expression of eYFP according to NKp46 expression in NKp46iCreR26ReYFP mice. (A) Schematic representation of the strategy used to generate NKp46iCre mice. (B) Flow cytometric measurement of eYFP and NKp46iCreR26ReYFP C D Gated on CD122+lin- NKp46 expressions on NK cells from spleen of .( and ) IMMUNOLOGY A BM cells Flow cytometric measurement of eYFP expression on gated NK cells (C)or indicated cell population (D) from indicated organs of NKp46iCreR26ReYFP (open histograms) and control NKp46iCre mice (gray histograms). Results are representative of three experiments. eYFP (31). Nkp46iCre/wt and R26ReYFP/wt mice were crossed to obtain NK1.1 iCre/wt eYFP/wt Nkp46 R26R mice heterozygous at both loci and re- Gated on CD122+NK1.1+lin- BM cells iCre eYFP iCre eYFP B Gated on CD122+lin-c-Kit- C ferred as to Nkp46 R26R thereafter. Nkp46 R26R CD11b- BM cells were generated to ensure the irreversible expression of the eYFP reporter gene in NKp46+ cells and their progeny, irrelevant of the 77% possible arrest in Nkp46 transcription.
Load more

Recommended publications
  • Primary Sjogren Syndrome: Focus on Innate Immune Cells and Inflammation
    Review Primary Sjogren Syndrome: Focus on Innate Immune Cells and Inflammation Chiara Rizzo 1, Giulia Grasso 1, Giulia Maria Destro Castaniti 1, Francesco Ciccia 2 and Giuliana Guggino 1,* 1 Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Rheumatology Section, University of Palermo, Piazza delle Cliniche 2, 90110 Palermo, Italy; [email protected] (C.R.); [email protected] (G.G.); [email protected] (G.M.D.C.) 2 Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Via L. De Crecchio 7, 80138 Naples, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-091-6552260 Received: 30 April 2020; Accepted: 29 May 2020; Published: 3 June 2020 Abstract: Primary Sjogren Syndrome (pSS) is a complex, multifactorial rheumatic disease that mainly targets salivary and lacrimal glands, inducing epithelitis. The cause behind the autoimmunity outbreak in pSS is still elusive; however, it seems related to an aberrant reaction to exogenous triggers such as viruses, combined with individual genetic pre-disposition. For a long time, autoantibodies were considered as the hallmarks of this disease; however, more recently the complex interplay between innate and adaptive immunity as well as the consequent inflammatory process have emerged as the main mechanisms of pSS pathogenesis. The present review will focus on innate cells and on the principal mechanisms of inflammation connected. In the first part, an overview of innate cells involved in pSS pathogenesis is provided, stressing in particular the role of Innate Lymphoid Cells (ILCs). Subsequently we have highlighted the main inflammatory pathways, including intra- and extra-cellular players.
    [Show full text]
  • Recombinant Human NCR3/Nkp300 Protein
    Leader in Biomolecular Solutions for Life Science Recombinant Human NCR3/NKp300 Protein Catalog No.: RP00179 Recombinant Sequence Information Background Species Gene ID Swiss Prot Natural Cytotoxicity Triggering Receptor 3, NCR3, also known as NKp30, or CD337, Human 259197 O14931 is a natural cytotoxicity receptor. NKp30 is expressed on both resting and activated NK cells of the CD56dim, CD16+ subset that account for more that 85% of NK cells Tags found in peripheral blood and spleen. NKp30 is absent from the CD56bright, CD16- C-Fc & 6×His subset that constitutes the majority of NK cells in lymph node and tonsil, however, its expression is up-regulated in these cells upon IL-2 activation .NKp30 is a Synonyms member of the immunoglobulin superfamily and one of three existing natural 1C7;CD337;DAAP-90L16.3;LY117;MALS cytotoxicity-triggering receptors. NKp30 is a glycosylated protein and is thought to ;NCR3;NKp30 be selectively expressed in resting and activated natural killer cells. NKp30 is a stimulatory receptor on human NK cells implicated in tumor immunity, and is capable of promoting or terminating dendritic cell maturation. NCR3 may play a role in inflammatory and infectious diseases. Product Information Source Purification Basic Information HEK293 cells > 95% by SDS- PAGE. Description Recombinant Human NCR3/NKp300 Protein is produced by HEK293 cells Endotoxin expression system. The target protein is expressed with sequence (Leu19-Thr138) < 0.1 EU/μg of the protein by LAL of human NCR3/NKp300 (Accession #NP_001138938.1) fused with an Fc, 6×His tag method. at the C-terminus. Formulation Bio-Activity Lyophilized from a 0.22 μm filtered Measured by its binding ability in a functional ELISA.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Associated B Cell Lymphoma and Nasopharyngeal Carcinoma
    Contribution of tumour cell signalling and the microenvironment to the pathogenesis of EBV- associated B cell lymphoma and nasopharyngeal carcinoma BY MAHA IBRAHIM A thesis submitted to The University of Birmingham For the degree of DOCTOR OF PHILOSOPHY Institute of Cancer and Genomic Sciences College of Medical and Dental Sciences University of Birmingham May 2018 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract In this thesis I have explored different components of the pathogenesis of several related EBV associated cancers. In the first part of the thesis I focus on the microenvironment of two of these cancers, nasopharyngeal carcinoma (NPC) and diffuse large B cell lymphoma (DLBCL). Our group has developed a therapeutic vaccine against EBV which has already been shown to be safe in patients with NPC. Therefore, in the first results chapter (chapter 3), I present a description of the phenotyping of expression of the immune microenvironment including immune checkpoint (ICP) genes and MHC class I and class II genes in NPC tissues. I showed for the first time in NPC tissue samples, two types of PD-L1 expressing tumours: diffuse and marginal.
    [Show full text]
  • Supplementary Table S5. Differentially Expressed Gene Lists of PD-1High CD39+ CD8 Tils According to 4-1BB Expression Compared to PD-1+ CD39- CD8 Tils
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Supplementary Table S5. Differentially expressed gene lists of PD-1high CD39+ CD8 TILs according to 4-1BB expression compared to PD-1+ CD39- CD8 TILs Up- or down- regulated genes in Up- or down- regulated genes Up- or down- regulated genes only PD-1high CD39+ CD8 TILs only in 4-1BBneg PD-1high CD39+ in 4-1BBpos PD-1high CD39+ CD8 compared to PD-1+ CD39- CD8 CD8 TILs compared to PD-1+ TILs compared to PD-1+ CD39- TILs CD39- CD8 TILs CD8 TILs IL7R KLRG1 TNFSF4 ENTPD1 DHRS3 LEF1 ITGA5 MKI67 PZP KLF3 RYR2 SIK1B ANK3 LYST PPP1R3B ETV1 ADAM28 H2AC13 CCR7 GFOD1 RASGRP2 ITGAX MAST4 RAD51AP1 MYO1E CLCF1 NEBL S1PR5 VCL MPP7 MS4A6A PHLDB1 GFPT2 TNF RPL3 SPRY4 VCAM1 B4GALT5 TIPARP TNS3 PDCD1 POLQ AKAP5 IL6ST LY9 PLXND1 PLEKHA1 NEU1 DGKH SPRY2 PLEKHG3 IKZF4 MTX3 PARK7 ATP8B4 SYT11 PTGER4 SORL1 RAB11FIP5 BRCA1 MAP4K3 NCR1 CCR4 S1PR1 PDE8A IFIT2 EPHA4 ARHGEF12 PAICS PELI2 LAT2 GPRASP1 TTN RPLP0 IL4I1 AUTS2 RPS3 CDCA3 NHS LONRF2 CDC42EP3 SLCO3A1 RRM2 ADAMTSL4 INPP5F ARHGAP31 ESCO2 ADRB2 CSF1 WDHD1 GOLIM4 CDK5RAP1 CD69 GLUL HJURP SHC4 GNLY TTC9 HELLS DPP4 IL23A PITPNC1 TOX ARHGEF9 EXO1 SLC4A4 CKAP4 CARMIL3 NHSL2 DZIP3 GINS1 FUT8 UBASH3B CDCA5 PDE7B SOGA1 CDC45 NR3C2 TRIB1 KIF14 TRAF5 LIMS1 PPP1R2C TNFRSF9 KLRC2 POLA1 CD80 ATP10D CDCA8 SETD7 IER2 PATL2 CCDC141 CD84 HSPA6 CYB561 MPHOSPH9 CLSPN KLRC1 PTMS SCML4 ZBTB10 CCL3 CA5B PIP5K1B WNT9A CCNH GEM IL18RAP GGH SARDH B3GNT7 C13orf46 SBF2 IKZF3 ZMAT1 TCF7 NECTIN1 H3C7 FOS PAG1 HECA SLC4A10 SLC35G2 PER1 P2RY1 NFKBIA WDR76 PLAUR KDM1A H1-5 TSHZ2 FAM102B HMMR GPR132 CCRL2 PARP8 A2M ST8SIA1 NUF2 IL5RA RBPMS UBE2T USP53 EEF1A1 PLAC8 LGR6 TMEM123 NEK2 SNAP47 PTGIS SH2B3 P2RY8 S100PBP PLEKHA7 CLNK CRIM1 MGAT5 YBX3 TP53INP1 DTL CFH FEZ1 MYB FRMD4B TSPAN5 STIL ITGA2 GOLGA6L10 MYBL2 AHI1 CAND2 GZMB RBPJ PELI1 HSPA1B KCNK5 GOLGA6L9 TICRR TPRG1 UBE2C AURKA Leem G, et al.
    [Show full text]
  • Natural Killer Cell Lymphoma Shares Strikingly Similar Molecular Features
    Leukemia (2011) 25, 348–358 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic cd T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro J Iqbal1, DD Weisenburger1, A Chowdhury2, MY Tsai2, G Srivastava3, TC Greiner1, C Kucuk1, K Deffenbacher1, J Vose4, L Smith5, WY Au3, S Nakamura6, M Seto6, J Delabie7, F Berger8, F Loong3, Y-H Ko9, I Sng10, X Liu11, TP Loughran11, J Armitage4 and WC Chan1, for the International Peripheral T-cell Lymphoma Project 1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA; 2Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA; 3Departments of Pathology and Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China; 4Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 5College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA; 6Departments of Pathology and Cancer Genetics, Aichi Cancer Center Research Institute, Nagoya University, Nagoya, Japan; 7Department of Pathology, University of Oslo, Norwegian Radium Hospital, Oslo, Norway; 8Department of Pathology, Centre Hospitalier Lyon-Sud, Lyon, France; 9Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea; 10Department of Pathology, Singapore General Hospital, Singapore and 11Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA Natural killer (NK) cell lymphomas/leukemias are rare neo- Introduction plasms with an aggressive clinical behavior.
    [Show full text]
  • Anti-NCR3 / Nkp30 Antibody (ARG59803)
    Product datasheet [email protected] ARG59803 Package: 100 μl anti-NCR3 / NKp30 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes NCR3 / NKp30 Tested Reactivity Hu, Ms, Rat Tested Application ICC/IF, IHC-P Host Rabbit Clonality Polyclonal Isotype IgG Target Name NCR3 / NKp30 Antigen Species Human Immunogen Recombinant fusion protein corresponding to aa. 20-140 of Human NCR3 (NP_667341.1). Conjugation Un-conjugated Alternate Names NK-p30; 1C7; CD antigen CD337; Activating natural killer receptor p30; NKp30; Natural cytotoxicity triggering receptor 3; MALS; LY117; Natural killer cell p30-related protein; CD337 Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:100 IHC-P 1:100 - 1:200 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 22 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/3 Bioinformation Gene Symbol NCR3 Gene Full Name natural cytotoxicity triggering receptor 3 Background The protein encoded by this gene is a natural cytotoxicity receptor (NCR) that may aid NK cells in the lysis of tumor cells.
    [Show full text]
  • Immune Suppressive Landscape in the Human Esophageal Squamous Cell
    ARTICLE https://doi.org/10.1038/s41467-020-20019-0 OPEN Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment ✉ Yingxia Zheng 1,2,10 , Zheyi Chen1,10, Yichao Han 3,10, Li Han1,10, Xin Zou4, Bingqian Zhou1, Rui Hu5, Jie Hao4, Shihao Bai4, Haibo Xiao5, Wei Vivian Li6, Alex Bueker7, Yanhui Ma1, Guohua Xie1, Junyao Yang1, ✉ ✉ ✉ Shiyu Chen1, Hecheng Li 3 , Jian Cao 7,8 & Lisong Shen 1,9 1234567890():,; Cancer immunotherapy has revolutionized cancer treatment, and it relies heavily on the comprehensive understanding of the immune landscape of the tumor microenvironment (TME). Here, we obtain a detailed immune cell atlas of esophageal squamous cell carcinoma (ESCC) at single-cell resolution. Exhausted T and NK cells, regulatory T cells (Tregs), alternatively activated macrophages and tolerogenic dendritic cells are dominant in the TME. Transcriptional profiling coupled with T cell receptor (TCR) sequencing reveal lineage con- nections in T cell populations. CD8 T cells show continuous progression from pre-exhausted to exhausted T cells. While exhausted CD4, CD8 T and NK cells are major proliferative cell components in the TME, the crosstalk between macrophages and Tregs contributes to potential immunosuppression in the TME. Our results indicate several immunosuppressive mechanisms that may be simultaneously responsible for the failure of immuno-surveillance. Specific targeting of these immunosuppressive pathways may reactivate anti-tumor immune responses in ESCC. 1 Department of Laboratory Medicine, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2 Institute of Biliary Tract Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3 Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
    [Show full text]
  • NK Cells and Cancer: You Can Teach Innate Cells New Tricks
    UCSF UC San Francisco Previously Published Works Title NK cells and cancer: you can teach innate cells new tricks. Permalink https://escholarship.org/uc/item/5t11r9h0 Journal Nature reviews. Cancer, 16(1) ISSN 1474-175X Authors Morvan, Maelig G Lanier, Lewis L Publication Date 2016 DOI 10.1038/nrc.2015.5 Peer reviewed eScholarship.org Powered by the California Digital Library University of California REVIEWS NK cells and cancer: you can teach innate cells new tricks Maelig G. Morvan and Lewis L. Lanier Abstract | Natural killer (NK) cells are the prototype innate lymphoid cells endowed with potent cytolytic function that provide host defence against microbial infection and tumours. Here, we review evidence for the role of NK cells in immune surveillance against cancer and highlight new therapeutic approaches for targeting NK cells in the treatment of cancer. Innate lymphoid cell Although they were discovered more than 40 years ago, other immune cells expressing NK cell receptors that may (ILC). A lymphocyte that natural killer (NK) cells have recently been attracting contribute to their antitumour immune responses. Given participates in the innate attention for their potential in immune-based ther- the successful anticancer therapeutic approaches involv- immune responses. ILCs are apies. Initially believed to be just an annoying back- ing blockade of T cell-directed immune checkpoints, we present in RAG-deficient (Rag1–/– and Rag2–/–) mice, ground activity in cytotoxicity assays or an artefact, discuss how these and new combination strategies could so do not require gene NK cells are now considered to be an important part also affect the antitumour functions of NK cells.
    [Show full text]
  • Human CD Marker Chart Reviewed by HLDA1 Bdbiosciences.Com/Cdmarkers
    BD Biosciences Human CD Marker Chart Reviewed by HLDA1 bdbiosciences.com/cdmarkers 23-12399-01 CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD Alternative Name Ligands & Associated Molecules T Cell B Cell Dendritic Cell NK Cell Stem Cell/Precursor Macrophage/Monocyte Granulocyte Platelet Erythrocyte Endothelial Cell Epithelial Cell CD1a R4, T6, Leu6, HTA1 b-2-Microglobulin, CD74 + + + – + – – – CD93 C1QR1,C1qRP, MXRA4, C1qR(P), Dj737e23.1, GR11 – – – – – + + – – + – CD220 Insulin receptor (INSR), IR Insulin, IGF-2 + + + + + + + + + Insulin-like growth factor 1 receptor (IGF1R), IGF-1R, type I IGF receptor (IGF-IR), CD1b R1, T6m Leu6 b-2-Microglobulin + + + – + – – – CD94 KLRD1, Kp43 HLA class I, NKG2-A, p39 + – + – – – – – – CD221 Insulin-like growth factor 1 (IGF-I), IGF-II, Insulin JTK13 + + + + + + + + + CD1c M241, R7, T6, Leu6, BDCA1 b-2-Microglobulin + + + – + – – – CD178, FASLG, APO-1, FAS, TNFRSF6, CD95L, APT1LG1, APT1, FAS1, FASTM, CD95 CD178 (Fas ligand) + + + + + – – IGF-II, TGF-b latency-associated peptide (LAP), Proliferin, Prorenin, Plasminogen, ALPS1A, TNFSF6, FASL Cation-independent mannose-6-phosphate receptor (M6P-R, CIM6PR, CIMPR, CI- CD1d R3G1, R3 b-2-Microglobulin, MHC II CD222 Leukemia
    [Show full text]
  • Downregulation of Carnitine Acyl-Carnitine Translocase by Mirnas
    Page 1 of 288 Diabetes 1 Downregulation of Carnitine acyl-carnitine translocase by miRNAs 132 and 212 amplifies glucose-stimulated insulin secretion Mufaddal S. Soni1, Mary E. Rabaglia1, Sushant Bhatnagar1, Jin Shang2, Olga Ilkayeva3, Randall Mynatt4, Yun-Ping Zhou2, Eric E. Schadt6, Nancy A.Thornberry2, Deborah M. Muoio5, Mark P. Keller1 and Alan D. Attie1 From the 1Department of Biochemistry, University of Wisconsin, Madison, Wisconsin; 2Department of Metabolic Disorders-Diabetes, Merck Research Laboratories, Rahway, New Jersey; 3Sarah W. Stedman Nutrition and Metabolism Center, Duke Institute of Molecular Physiology, 5Departments of Medicine and Pharmacology and Cancer Biology, Durham, North Carolina. 4Pennington Biomedical Research Center, Louisiana State University system, Baton Rouge, Louisiana; 6Institute for Genomics and Multiscale Biology, Mount Sinai School of Medicine, New York, New York. Corresponding author Alan D. Attie, 543A Biochemistry Addition, 433 Babcock Drive, Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, (608) 262-1372 (Ph), (608) 263-9608 (fax), [email protected]. Running Title: Fatty acyl-carnitines enhance insulin secretion Abstract word count: 163 Main text Word count: 3960 Number of tables: 0 Number of figures: 5 Diabetes Publish Ahead of Print, published online June 26, 2014 Diabetes Page 2 of 288 2 ABSTRACT We previously demonstrated that micro-RNAs 132 and 212 are differentially upregulated in response to obesity in two mouse strains that differ in their susceptibility to obesity-induced diabetes. Here we show the overexpression of micro-RNAs 132 and 212 enhances insulin secretion (IS) in response to glucose and other secretagogues including non-fuel stimuli. We determined that carnitine acyl-carnitine translocase (CACT, Slc25a20) is a direct target of these miRNAs.
    [Show full text]
  • RT² Profiler PCR Array (384-Well Format) Human Inflammatory Response & Autoimmunity
    RT² Profiler PCR Array (384-Well Format) Human Inflammatory Response & Autoimmunity Cat. no. 330231 PAHS-3803ZE For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 7900HT (384-well block), Format E ViiA™ 7 (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (384-well block) Format G Description The Human Inflammatory Response & Autoimmunity RT² Profiler PCR Array profiles the expression of 370 key genes involved in immune response during autoimmunity and inflammation. It represents the expression of inflammatory cytokines, chemokines, and their receptors. It also contains genes related to the production and metabolism of cytokines. Genes involved in cytokine-cytokine receptor interactions are as well as thoroughly researched panels of genes involved in the acute-phase, inflammatory, and humoral immune responses. Using real-time PCR, you can easily and reliably analyze the expression of a focused panel of genes related to autoimmunity and inflammation with this array. For further details, consult the RT² Profiler PCR Array Handbook. Sample & Assay Technologies Shipping and storage RT² Profiler PCR Arrays in formats E and G are shipped at ambient temperature, on dry ice, or blue ice packs depending on destination and accompanying products. For long term storage, keep plates at –20°C. Note: Ensure that you have the correct RT² Profiler PCR Array format for your real-time cycler (see table above). Note: Open the package and store
    [Show full text]